Skip to content
Latest News
Startups, Latest News

Nectero Medical begins Phase II/III Clinical Trials

Nectero Medical is a clinical-stage biotech startup that is developing novel therapies to address the challenges of treating aneurysmal disease. The company's focus is on improving outcomes for patients with abdominal aortic aneurysms (AAA), a condition that affects over 1 million Americans.

The foundation of Nectero Medical's approach is a patented compound developed by and licensed from Dr. Naren Vyavahare's lab in the Clemson University's Department of Bioengineering. This compound is designed to stabilize elastin and improve the strength of the affected tissue, which is a critical factor in the management of aneurysmal disease.

Nectero Medical's lead product, the Nectero EAST System, is a single-use, endovascular system that delivers this stabilizing compound directly to the aneurysmal wall. The system consists of a dual-balloon delivery catheter and a stabilizer mixture containing pentagalloyl glucose (PGG), which can bind to elastin and collagen to potentially reinforce the aortic vessel wall and reduce the risk of further degradation.

This past year, Nectero Medical has begun Phase II/III clinical trials to evaluate the safety and efficacy of the Nectero EAST System in treating patients with small-to-medium sized abdominal aortic aneurysms, with a diameter between 3.5 - 5.0 cm. Current treatment options are primarily reserved for larger aneurysms or rapidly expanding ones, leaving a significant population of patients with smaller AAAs without an approved therapeutic option beyond surveillance. However, the Nectero EAST System offers a minimally invasive approach that can be completed in under an hour and does not require any specialized tools for vascular surgeons trained in endovascular techniques. Importantly, the procedure does not leave behind any permanent implants, allowing for potential future interventions if necessary.

As the company continues to advance its clinical trials, Nectero Medical remains focused on developing innovative solutions to improve the lives of those affected by aneurysmal disease. Click here for more information and updates on Nectero Medical: https://necteromedical.com/ 

Get Started
Ready to Get Started?

Contact our team at CURF

Contact CURF